MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

05/28/2014 by Brad Perriello

Integrity Applications looks beyond optical sensors with its GlucoTrack Model DF-F, which uses ultrasonic, electromagnetic and thermal technology to measure physiological changes associated with blood glucose levels.

Diabetes: Integrity Applications looks beyond optical for blood glucose

A 23-year career in the Israeli Navy might not seem like the ideal background for a medical device company chief, but for Integrity Applications chairman & CEO Avner Gal it turned out to be the perfect pedigree.

Gal told that his time as a developing engineer in...

05/26/2014 by Brian Johnson

Former NBA player Jonathan Bender tries his hand at entrepreneurship, aiming to bring the physical therapy device he invented to the U.S. market.

JB photo

Joint pain cut years from Jonathan Bender's professional basketball career, but it also gave him a future.

The former NBA player, who made the jump from high school directly to the pros in 1999, spent 7 injury-plagued seasons with the Indiana Pacers before bowing out in 2006 (Bender returned in 2010 for a half season with the New York Knicks).


05/23/2014 by Arezu Sarvestani

Battelle engineering manager Melissa Masters tells how insights ranging from national security to aeronautics can inform the creation of disruptive new medical devices.

Turning diversification into disruption: Battelle pulls inspiration from surprising sources

Medical device executives and Ted Talk-ers love comparing the medtech industry to consumer electronics or aeronautics when making grand points about the market, but at Battelle cross-...

05/19/2014 by Arezu Sarvestani

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

PETA targets Medtronic, Boston Scientific for animal experiments

Animal rights activists have long raised concerns about some of the largest medical device companies, taking up minuscule stock holdings to gain access to shareholder meetings at a raft of medtech makers.

People for the Ethical Treatment...

05/16/2014 by Arezu Sarvestani

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

In depth in Silicon Valley: Mobile health and medtech's digital future with AliveCor CEO Euan Thomson

When Euan Thomson left Accuray (NSDQ:...

03/25/2014 by Chris Walker

Definiens CEO Thomas Heydler discusses his ambition to position his company at the forefront of the coming revolution in personalized and predictive medicines. Q&A – Definiens CEO Thomas Hedlyer on personalized medicine

Definiens CEO Thomas Heydler is leading the charge to put his company at the forefront of personalized medicine, starting with a big data approach in order help treat patients.

The imaging software company, started by Nobel Physics prize winner Gerd Binnig, seeks to identify and analyze biomedical...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp